Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial
- Resource Type
- Article
- Source
- In
Journal of the Neurological Sciences 2005 239(1):67-74 - Subject
- Language
- ISSN
- 0022-510X